Castle Biosciences: Tobin Juvenal proposes $452K sale

The proposed transaction is tied to a selling plan dated May 28, 2026, intended to comply with Rule 10b5-1(c).

Available on EDGAR 11/09/2026 - 06:38 PM EST Accepted by SEC EDGAR 11/09/2026 - 06:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Castle Biosciences, Inc. (CSTL) Chief Commercial Officer Tobin Juvenal reported a proposed sale of 13,154 common shares, with an aggregate market value of $452,234.52 and an approximate sale date of November 9, 2026. The notice lists 30,818,291 common shares outstanding. The proposed sale is in connection with a selling plan dated May 28, 2026, intended to comply with Rule 10b5-1(c). Goldman Sachs & Co. LLC signed on Juvenal’s behalf.

Key Figures

Proposed shares to be sold: 13,154 shares Aggregate market value: $452,234.52 Common shares outstanding: 30,818,291 shares

3 metrics

Proposed shares to be sold 13,154 shares Approximate sale date November 9, 2026

Aggregate market value $452,234.52 Proposed sale

Common shares outstanding 30,818,291 shares Number reported in the securities information

Key Terms

Rule 10b5-1(c), Restricted Stock Units, Performance Awards

3 terms

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Restricted Stock Units financial

"Acquired as compensation -- Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Performance Awards financial

"Acquired as compensation -- Performance Awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CSTL shares does Chief Commercial Officer Tobin Juvenal propose to sell?

Tobin Juvenal reported a proposed sale of 13,154 common shares, with an aggregate market value of $452,234.52. The approximate sale date is November 9, 2026.

Was Tobin Juvenal’s proposed CSTL sale connected to a Rule 10b5-1 plan?

Yes. The proposed sale is in connection with a selling plan dated May 28, 2026, which is described as intended to comply with Rule 10b5-1(c).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001856542
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Castle Biosciences, Inc.
SEC File Number	001-38984
Address of Issuer	1500 W. Parkwood Ave Suite 400 Friendswood TEXAS 77546
Phone	1-866-788-9007
Name of Person for Whose Account the Securities are To Be Sold	Tobin Juvenal
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Commercial Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	13154	452234.52	30818291	11/09/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/10/2023	Acquired as compensation -- Restricted Stock Units	Issuer			1012	12/10/2023	Compensation
Common	12/09/2023	Acquired as compensation -- Restricted Stock Units	Issuer			2208	12/09/2023	Compensation
Common	08/08/2025	Acquired as compensation -- Performance Awards	Issuer			6346	08/08/2025	Compensation
Common	02/29/2024	Acquired as compensation -- Restricted Stock Awards	Issuer			1272	02/29/2024	Compensation
Common	08/31/2021	Acquired as compensation -- Restricted Stock Awards	Issuer			705	08/31/2021	Compensation
Common	02/28/2020	Acquired as compensation -- Restricted Stock Awards	Issuer			905	02/28/2020	Compensation
Common	02/26/2021	Acquired as compensation -- Restricted Stock Awards	Issuer			706	02/26/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	08/17/2026	1730	51191.84
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	08/25/2026	9050	317112.09
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	08/31/2026	1730	56760.97
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/14/2026	1653	53423.31
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/14/2026	1653	53438.85
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/15/2026	3294	115759.07
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/29/2026	1644	58409.02
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/29/2026	1644	58436.14
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/29/2026	2255	79920.81
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	09/30/2026	1034	35362.59
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	10/28/2026	6578	239190.22
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	10/26/2026	1644	54277.01
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	10/26/2026	1644	54278.65
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	10/12/2026	1644	55200.27
Tobin Juvenal 1500 W. Parkwood Ave Suite 400 Friendswood TX 77546	Common	10/12/2026	1644	55216.55

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 5/28/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	11/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Tobin Juvenal
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)